Key result
The anti-P-selectin antibody PB1.3 reduced infarct size by about 25% but did not improve global or regional left ventricular function over 48 hours of reperfusion.
Why the study?
Although inhibition of P-selectin reduces short-term myocardial injury after ischemia and reperfusion, its ability to provide meaningful long-term protection and preserve left ventricular function was unknown.
Does the blocking anti-P-selectin antibody PB1.3 reduce infarct size and prevent neutrophil activation in dogs undergoing coronary occlusion and reperfusion?
RCT (n=20)
Does the blocking anti-P-selectin antibody PB1.3 reduce infarct size and prevent neutrophil activation in dogs undergoing coronary occlusion and reperfusion?
In a canine model of ischemia-reperfusion, P-selectin inhibition prevented early neutrophil activation and modestly reduced infarct size but failed to improve left ventricular function.
Answers are grounded in this paper and cite their sources.
P-selectin blockade does not yet inform clinical reperfusion therapy; leaves open its potential in human ischemia-reperfusion injury.
OBJECTIVES: This study was designed to determine whether antibody neutralization of the adhesion protein P-selectin would prevent neutrophil activation and reduce myocardial reperfusion injury. BACKGROUND: Although inhibition of P-selectin markedly reduces short-term myocardial injury after ischemia and reperfusion, it is unknown whether it can provide meaningful long-term protection and preserve left ventricular function. METHODS: Closed-chest dogs underwent 90 min left anterior descending coronary artery occlusion and 48 h reperfusion, and were randomized to 1) a treatment group (n = 11) receiving 1 mg/kg of the blocking anti-P-selectin antibody PB1.3, or 2) a control group receiving 1 mg/kg PNB1.6 (nonblocking antibody against P-selectin, n = 7) or an equivalent volume of saline (n = 2) 10 min before reperfusion. Infarct size was assessed postmortem by triphenyl tetrazolium chloride staining. Contrast left ventriculography was used to measure left ventricular function. Activation of circulating polymorphonuclear neutrophils (PMNs) was assessed by an increase in surface CD18 expression. RESULTS: Neutrophil activation was observed at 30 min after reperfusion in the control group, but was abolished in the treatment group. Infarct size was reduced about 25% in the treatment group after controlling for variations in ischemic blood flow (p = 0.003, by analysis of covariance). However, this protective effect was not associated with preservation of blood flow to the ischemic-reperfused myocardium, nor with any improvement in global or regional left ventricular function. CONCLUSIONS: The anti-P-selectin antibody PB1.3 prevented early PMN activation, but had only a modest long-term infarct-limiting effect over 48 h reperfusion. Adhesion molecules other than P-selectin may mediate delayed PMN activation and accumulation in reperfused myocardium.
No takes yet. Share an insight, caveat, or question.
Arai et al. (1999) conducted an RCT in myocardial reperfusion injury (n=20). anti-P-selectin antibody PB1.3 vs. PNB1.6 (nonblocking antibody) or saline was evaluated on Infarct size (25% reduction, p=0.003). The anti-P-selectin antibody PB1.3 reduced infarct size by about 25% but did not improve global or regional left ventricular function over 48 hours of reperfusion.
Synapse has enriched 10 related papers. Consider them for comparative context: